<DOC>
	<DOCNO>NCT00059878</DOCNO>
	<brief_summary>RATIONALE : Antifungals voriconazole may effective control fungal infection . Combining voriconazole interferon gamma may effective voriconazole alone treat fungal infection . PURPOSE : Randomized phase II trial compare effectiveness voriconazole without interferon gamma treat patient aspergillosis fungal infection .</brief_summary>
	<brief_title>Voriconazole With Without Interferon Gamma Treating Patients With Aspergillosis Other Fungal Infections</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety profile voriconazole interferon gamma patient invasive aspergillosis filamentous fungal infection . - Compare efficacy possible heterogeneity efficacy voriconazole without interferon gamma across different patient sub-populations , term design large phase II pivotal phase III study . - Determine time partial complete response rate response ( week 6 12 end treatment follow-up ) patient receive interferon gamma . - Compare proportion patient least two-fold reduction galactomannan antigenemia titer 6 12 week end treatment regimen . - Determine surrogate immunologic marker response interferon gamma , functional integrity anti-fungal activity phagocytic cell ( neutrophil , monocyte , macrophage ) , nonphagocytic effector cell ( natural killer T cell ) patient . OUTLINE : This randomize , double-blind , multicenter , pilot study . Patients stratify accord age ( 18 vs 18 ) absolute neutrophil count ( le 500/mm^3 v least 500/mm^3 ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive voriconazole ( IV 80-120 minute first 3 dos orally every 12 hour subsequent dos ) 3 time per week interferon gamma subcutaneously ( SC ) 3 time per week . - Arm II : Patients receive voriconazole arm I placebo SC 3 time per week . In arm , treatment continue 12 week absence disease progression unacceptable toxicity . Patients follow 4 week . PROJECTED ACCRUAL : A total 88 patient ( 44 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Proven probable invasive aspergillosis filamentous fungal infection cytology , histopathology , culture within past 7 day Presenting 1 follow : Cancer Aplastic anemia Inherited immunodeficiency Autoimmune deficiency disorder Acquired immunodeficiency Recipient autologous peripheral blood stem cell bone marrow transplantation CNS aspergillosis filamentous fungal infection allow No invasive zygomycosis infection PATIENT CHARACTERISTICS : Age 2 Performance status Not specify Life expectancy At least 7 day Hematopoietic Not specify Hepatic ALT great 5 time upper limit normal Renal Creatinine clearance least 30 mL/min Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception No prior significant CNS disorder ( e.g. , multiple sclerosis uncontrolled seizure ) No prior grade 3 4 toxicity severe allergic reaction interferon gamma No prior intolerance hypersensitivity voriconazole azoles No acute chronic graftversushost disease No condition would preclude study compliance PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics No prior allogeneic peripheral blood bone marrow transplantation No concurrent interferon alfa Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery No prior solid organ transplantation Other Prior voriconazole allow At least 24 hour since prior administration follow : Astemizole Cisapride Pimozide Quinidine Sirolimus Terfenadine Rifabutin Ergot alkaloid Sildenafil citrate Amiodarone Flecainide Systemic lidocaine More 14 day since prior longacting barbiturate , carbamazepine , rifampin No concurrent systemic antifungal drug No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2004</verification_date>
	<keyword>infection</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>